Welcome to our dedicated page for Janux Therapeutics SEC filings (Ticker: JANX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Janux Therapeutics filings document a clinical-stage biopharmaceutical issuer developing tumor-activated immunotherapies through the TRACTr, TRACIr and ARM platforms. Recent 8-K reports furnish financial results and business updates covering clinical programs such as JANX007, JANX014, JANX011 and JANX008, as well as cash-position commentary and pipeline prioritization.
The company’s regulatory record also includes a material definitive agreement for the Bristol Myers Squibb collaboration, with license, development, commercialization, milestone and royalty terms. Proxy and governance filings document director elections, board-classification matters, executive compensation, pay-versus-performance disclosure and officer or director changes.
Janux Therapeutics director Winston Kung received new equity awards. He was granted 5,500 restricted stock units, each representing one share of common stock, and 15,500 stock options with an exercise price of $13.66 per share.
The RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to continuous service. The options vest in equal monthly installments over the 12 months following June 11, 2026, and will in any case be fully vested by the next annual meeting, also subject to continued service. After the grant, Kung directly holds 11,750 shares of common stock.
Janux Therapeutics, Inc. director Natasha Hernday received new equity compensation awards. She was granted 5,500 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to her continuous service.
She was also granted a stock option for 15,500 shares of common stock at an exercise price of $13.66 per share, vesting in equal monthly installments over the 12 months following June 11, 2026 and fully vesting no later than the next annual stockholder meeting, contingent on continued service. Following these grants, she directly holds 15,481 shares of common stock.
Janux Therapeutics director Eric Dobmeier received new equity awards. He was granted 5,500 restricted stock units, each representing one share of common stock, which will vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to continued service.
He was also granted options to buy 15,500 shares of common stock at an exercise price of $13.66 per share, expiring on June 10, 2036. These options vest in equal monthly installments over the 12 months following June 11, 2026 and will in any case be fully vested by the next annual stockholder meeting, subject to continued service. Following these grants, he directly holds 15,481 common shares.
Janux Therapeutics director Vickie L. Capps received new equity awards. She was granted 5,500 restricted stock units, each convertible into one share of common stock, increasing her direct holdings to 79,598 shares. She also received options on 15,500 shares at an exercise price of $13.66 per share, vesting over 12 months and fully by the next annual stockholder meeting, subject to continued service.
Janux Therapeutics director Ronald W. Barrett received new equity awards. He was granted 5,500 restricted stock units, each representing one share of common stock, increasing his direct common stock holdings to 11,750 shares. He also received a stock option for 15,500 shares at an exercise price of $13.66 per share, expiring on June 10, 2036.
The RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to his continuous service. The option vests in equal monthly installments over the 12 months following June 11, 2026, and will in any case be fully vested by the next annual stockholder meeting, also contingent on continued service.
Janux Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. As of the April 17, 2026 record date, 60,961,546 shares of common stock were outstanding, and 53,744,922 shares were present or represented by proxy.
Stockholders elected Class II directors Natasha Hernday and Eric Dobmeier to serve until the 2029 annual meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved, on an advisory basis, the compensation of named executive officers.
Janux Therapeutics, Inc. reported that Chief Corp. & Business Development Officer Janeen Noel Doyle disposed of 4,059 shares of common stock on June 2, 2026 at a weighted average price of $14.029 per share. According to the footnotes, these shares were automatically sold to cover tax withholding obligations tied to the vesting of restricted stock units, indicating a routine, non-discretionary transaction rather than an active portfolio decision. Following this sale, Doyle directly holds 75,941 shares of Janux Therapeutics common stock.
JANX filed a Form 144 disclosing a proposed sale of 4,059 shares of Common Stock tied to restricted stock units vesting under a registered plan. The RSUs vested on 06/01/2026 and the filing shows a broker address for Morgan Stanley Smith Barney and a filing date of 06/02/2026.
Janus Henderson Group plc reports beneficial ownership of 4,196,409 shares of Janux Therapeutics, Inc., representing 6.9% of the class as disclosed in an Amendment No. 5 to Schedule 13G/A.
The filing states the shares are held by multiple Janus Henderson asset managers exercising shared voting and shared dispositive power over 4,196,409 shares. The filing includes a disclaimeral statement about dividend and sale rights and lists subsidiary/exhibit references for Item 7.
Janux Therapeutics Vice President of Accounting Maria Dobek reported an open-market sale of 2,038 shares of Janux Therapeutics common stock at $14.17 per share on May 11, 2026. After this transaction, she continues to hold 32,270 shares directly.